Abstract

Background

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation. Experimental evidence suggests that fluvastatin may, independent of any lipid lowering action, exert a greater direct inhibitory effect on proliferating vascular myocytes than other statins. The FLARE (Fluvastatin Angioplasty Restenosis) Trial was conceived to evaluate the ability of fluvastatin 40mg twice daily to reduce restenosis after successful coronary balloon angioplasty (PTCA).

Methods

Patients were randomized to either placebo or fluvastatin 40mg twice daily beginning 2–4 weeks prior to planned PTCA and continuing after a successful PTCA (without the use of a stent), to follow-up angiography at 26±2 weeks. Clinical follow-up was completed at 40 weeks. The primary end-point was angiographic restenosis, measured by quantitative coronary angiography at a core laboratory, as the loss in minimal luminal diameter during follow-up. Clinical end-points were death, myocardial infarction, coronary artery bypass graft surgery or re-intervetion, up to 40 weeks after PTCA.

Results

Of 1054 patients randomized, 526 were allocated to fluvastatin and 528 to placebo. Among these, 409 in the fluvastatin group and 427 in the placebo group were included in the intention-to-treat analysis, having undergone a successful PTCA after a minimum of 2 weeks of pre-treatment. At the time of PTCA, fluvastatin had reduced LDL cholesterol by 37% and this was maintained at 33% at 26 weeks. There was no difference in the primary end-point between the treatment groups (fluvastatin 0·23±0·49mm vs placebo 0·23±0·52mm,P=0·95) or in the angiographic restenosis rate (fluvastatin 28%, placebo 31%, chi-squareP=0·42), or in the incidence of the composite clinical end-point at 40 weeks (22·4% vs 23·3%; logrankP=0·74). However, a significantly lower incidence of total death and myocardial infarction was observed in six patients (1·4%) in the fluvastatin group and 17 (4·0%) in the placebo group (log rankP=0·025).

Conclusion

Treatment with fluvastatin 80mg daily did not affect the process of restenosis and is therefore not indicated for this purpose. However, the observed reduction in mortality and myocardial infarction 40 weeks after PTCA in the fluvastatin treated group has not been previously reported with statin therapy. Accordingly, a priori investigation of this finding is indicated and a new clinical trial with this intention is already underway.

f1
Correspondence: Prof. P. W. Serruys, MD, PhD, Thoraxcenter Bd 418, Academic Hospital, Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

References

1
Brown
G
, Fischer LD, Schaeffer SM. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B.
N Engl J Med
 .
1990
;
264
:
3007
–3012
2
Blankenhorn
DH
. Blood lipids and human atherosclerosis regression: the angiographic evidence.
Curr Opin Lipidol
 .
1991
;
2
:
2324
–2329
3
Vaughan
CJ
, Murphy MB, Buckley BM. Statins do more than just lower cholesterol.
Lancet
 .
1996
;
348
:
1079
–1082
4
Corsini
A
, Mazzotti M, Raitevi M. Relationship between mevalonate pathway and arterial myocyte prolifevatim: in vitro studies with inhibitors of HMG-CoA reductaze.
Atherosclerosis
 .
1993
;
101
:
117
–125
5
Soma
MR
, Donetti E, Parolini C. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
Arterioscler Thromb
 .
1993
;
13
:
571
–578
6
Ozaki
Y
, Keane D, Herrman JP. Coronary arteriography for quantitative analysis: an experimental and clinical comparison of cinefilm and video recordings.
Am Heart J
 .
1995
;
129
:
471
–475
7
Serruys
PW
, Rutsch W, Heyndrickx GR. Prevention of restenosis after percutaneous transluminal coronary angi-oplasty with thromboxane A2 receptor blockade. A randomized, double blind, placebo controlled trial.
Circulation
 .
1991
;
84
:
1568
–1580
8
Circulation
 .
1992
;
86
:
100
–111
9
Serruys
PW
, Klein W, Thijssen JPG. Evaluation of Ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicentre randomized double-blind placebo-controlled trial.
Circulation
 .
1993
;
88
:
1588
–1601
10
Faxon
DP
. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
J Am Coll Cardiol
 .
1995
;
25
:
362
–369
11
Foley
DP
, Bonnier H, Jackson G, Macaya C, Sheperd J, Vrolix M, Serruys PW. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial.
Am J Cardiol
 .
1994
;
73
:
50D
–61D
12
Lipid Research Clinics Manual of Laboratory Operations. : Government printing office; 1975.
13
Herrman
JPR
, Azar A, Umans VAWM, Boersma E, van Es GA, Serruys PW. Inter- and intra-observer variability in the qualitative categorization of coronary angiograms.
Int J Cardiac Imag
 .
1996
;
12
:
21
–30
14
Serruys
PW
, Foley DP, de Feyter PJ. Quantitative Coronary Angiography in Clinical Practice. Dordrecht, Boston, London: Kluwer Academic Publishers; 1994.
15
Shepherd
J
. Fibrates and statins in the treatment of hyper-lipidaemia: an appraisal of their efficacy and safety.
Eur Heart J
 .
1995
;
16
:
5
–13
16
Corsini
A
, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibition of proliferation of arterial smooth muscle cells by Fluvastatin.
Lancet
 .
1996
;
348
:
1584
17
Foley
DP
, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty.
Circulation
 .
1994
;
90
:
1239
–1251
18
Weintraub
WS
, Boccuzzi SJ, Klein JL. Lack of effect of lovastatin on restenosis after coronary angioplasty.
N Engl J Med
 .
1994
;
331
:
1331
–1337
19
Bertrand
ME
, McFadden EP, Fruchart JC, Predict trial investigators. Effect of Pravastatin on Angio-graphic restenosis after coronary balloon angioplasty.
J Am Coll Cardiol
 .
1997
;
30
:
863
–869
20
Foley
DP
, Melkert R, Umans VA. Differences in restenosis propensity of devices for transluminal coronary intervention: A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implan-tation and excimer laser angioplasty.
Eur Heart J
 .
1995
;:
21
Keane
D
, Haase J, Slager CJ. Comparative validation of quantitative coronary angiography systems. Results and implications from a multicenter study using a standardized approach.
Circulation
 .
1995
;
91
:
2174
–2183
22
Wilcox
JN
, Waksman R, King SB, Scott N. The role of the adventitia in arterial response to angioplasty: the effect of intravascular radiation.
Int J Radiation Oncol Biol Phys
 .
1996
;
36
:
789
–796
23
Camenzind
E
, Bakker WH, Reijs A. Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics.
Circulation
 .
1997
;
96
:
154
–165
24
Mintz
GS
, Popma JJ, Pichard AD. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.
Circulation
 .
1996
;
94
:
35
–43
25
Hoffmann
R
, Mintz GS, Dussaillant GR. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.
Circulation
 .
1994
;
92
:
1247
–1254
26
Lancet
 .
1995
;
344
:
1383
–1389
27
Sacks
FM
, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med
 .
1996
;
335
:
1001
–1009
28
Sheperd
J
, Cobbe M, Ford I. Prevention of heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med
 .
1995
;
333
:
1301
–1307
29
Colli
S
, Eligini S, Lalli M. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis.
Arterioscler Thromb Vasc Biol
 .
1997
;
17
:
265
–272
30
Bevilacqua
M
, Bettica P, Milani M. Effect of Fluvastatin on lipids and fibrinolysis in coronary artery disease.
Am J Cardiol
 .
1997
;
79
:
84
–86

Comments

0 Comments